Use of prostate systematic and targeted biopsy on the basis of multiparametric MRI in biopsy-naive patients (MRI-FIRST): a prospective, multicentre, paired diagnostic study - PubMed (original) (raw)
Comparative Study
. 2019 Jan;20(1):100-109.
doi: 10.1016/S1470-2045(18)30569-2. Epub 2018 Nov 21.
Philippe Puech 2, Raphaële Renard-Penna 3, Michel Claudon 4, Catherine Roy 5, Florence Mège-Lechevallier 6, Myriam Decaussin-Petrucci 7, Marine Dubreuil-Chambardel 8, Laurent Magaud 9, Laurent Remontet 10, Alain Ruffion 11, Marc Colombel 12, Sébastien Crouzet 12, Anne-Marie Schott 9, Laurent Lemaitre 2, Muriel Rabilloud 10, Nicolas Grenier 13; MRI-FIRST Investigators
Collaborators, Affiliations
- PMID: 30470502
- DOI: 10.1016/S1470-2045(18)30569-2
Comparative Study
Use of prostate systematic and targeted biopsy on the basis of multiparametric MRI in biopsy-naive patients (MRI-FIRST): a prospective, multicentre, paired diagnostic study
Olivier Rouvière et al. Lancet Oncol. 2019 Jan.
Abstract
Background: Whether multiparametric MRI improves the detection of clinically significant prostate cancer and avoids the need for systematic biopsy in biopsy-naive patients remains controversial. We aimed to investigate whether using this approach before biopsy would improve detection of clinically significant prostate cancer in biopsy-naive patients.
Methods: In this prospective, multicentre, paired diagnostic study, done at 16 centres in France, we enrolled patients aged 18-75 years with prostate-specific antigen concentrations of 20 ng/mL or less, and with stage T2c or lower prostate cancer. Eligible patients had been referred for prostate multiparametric MRI before a first set of prostate biopsies, with a planned interval of less than 3 months between MRI and biopsies. An operator masked to multiparametric MRI results did a systematic biopsy by obtaining 12 systematic cores and up to two cores targeting hypoechoic lesions. In the same patient, another operator targeted up to two lesions seen on MRI with a Likert score of 3 or higher (three cores per lesion) using targeted biopsy based on multiparametric MRI findings. Patients with negative multiparametric MRI (Likert score ≤2) had systematic biopsy only. The primary outcome was the detection of clinically significant prostate cancer of International Society of Urological Pathology grade group 2 or higher (csPCa-A), analysed in all patients who received both systematic and targeted biopsies and whose results from both were available for pathological central review, including patients who had protocol deviations. This study is registered with ClinicalTrials.gov, number NCT02485379, and is closed to new participants.
Findings: Between July 15, 2015, and Aug 11, 2016, we enrolled 275 patients. 24 (9%) were excluded from the analysis. 53 (21%) of 251 analysed patients had negative (Likert ≤2) multiparametric MRI. csPCa-A was detected in 94 (37%) of 251 patients. 13 (14%) of these 94 patients were diagnosed by systematic biopsy only, 19 (20%) by targeted biopsy only, and 62 (66%) by both techniques. Detection of csPCa-A by systematic biopsy (29·9%, 95% CI 24·3-36·0) and targeted biopsy (32·3%, 26·5-38·4) did not differ significantly (p=0·38). csPCa-A would have been missed in 5·2% (95% CI 2·8-8·7) of patients had systematic biopsy not been done, and in 7·6% (4·6-11·6) of patients had targeted biopsy not been done. Four grade 3 post-biopsy adverse events were reported (3 cases of prostatitis, and 1 case of urinary retention with haematuria).
Interpretation: There was no difference between systematic biopsy and targeted biopsy in the detection of ISUP grade group 2 or higher prostate cancer; however, this detection was improved by combining both techniques and both techniques showed substantial added value. Thus, obtaining a multiparametric MRI before biopsy in biopsy-naive patients can improve the detection of clinically significant prostate cancer but does not seem to avoid the need for systematic biopsy.
Funding: French National Cancer Institute.
Copyright © 2019 Elsevier Ltd. All rights reserved.
Comment in
- Exclusive MRI-targeted biopsy: not so fast.
Jayadevan R, Marks LS. Jayadevan R, et al. Lancet Oncol. 2019 Jan;20(1):9-10. doi: 10.1016/S1470-2045(18)30607-7. Epub 2018 Nov 21. Lancet Oncol. 2019. PMID: 30470503 No abstract available. - Re: Use of Prostate Systematic and Targeted Biopsy on the Basis of Multiparametric MRI in Biopsy-naive Patients (MRI-FIRST): A Prospective, Multicentre, Paired Diagnostic Study.
Carlsson SV, Eastham JA. Carlsson SV, et al. Eur Urol. 2019 Oct;76(4):534-535. doi: 10.1016/j.eururo.2019.04.022. Epub 2019 May 4. Eur Urol. 2019. PMID: 31064692 No abstract available. - Using Multiparametric Magnetic Resonance Imaging to Shift Prostate Cancer Diagnosis Toward Clinically Significant Disease and Minimize Overdiagnosis (and Overtreatment).
Henry A. Henry A. Int J Radiat Oncol Biol Phys. 2019 Dec 1;105(5):915-917. doi: 10.1016/j.ijrobp.2019.09.040. Int J Radiat Oncol Biol Phys. 2019. PMID: 31748142 Review. No abstract available.
Similar articles
- Head-to-head Comparison of Transrectal Ultrasound-guided Prostate Biopsy Versus Multiparametric Prostate Resonance Imaging with Subsequent Magnetic Resonance-guided Biopsy in Biopsy-naïve Men with Elevated Prostate-specific Antigen: A Large Prospective Multicenter Clinical Study.
van der Leest M, Cornel E, Israël B, Hendriks R, Padhani AR, Hoogenboom M, Zamecnik P, Bakker D, Setiasti AY, Veltman J, van den Hout H, van der Lelij H, van Oort I, Klaver S, Debruyne F, Sedelaar M, Hannink G, Rovers M, Hulsbergen-van de Kaa C, Barentsz JO. van der Leest M, et al. Eur Urol. 2019 Apr;75(4):570-578. doi: 10.1016/j.eururo.2018.11.023. Epub 2018 Nov 23. Eur Urol. 2019. PMID: 30477981 - The Additive Diagnostic Value of Prostate-specific Membrane Antigen Positron Emission Tomography Computed Tomography to Multiparametric Magnetic Resonance Imaging Triage in the Diagnosis of Prostate Cancer (PRIMARY): A Prospective Multicentre Study.
Emmett L, Buteau J, Papa N, Moon D, Thompson J, Roberts MJ, Rasiah K, Pattison DA, Yaxley J, Thomas P, Hutton AC, Agrawal S, Amin A, Blazevski A, Chalasani V, Ho B, Nguyen A, Liu V, Lee J, Sheehan-Dare G, Kooner R, Coughlin G, Chan L, Cusick T, Namdarian B, Kapoor J, Alghazo O, Woo HH, Lawrentschuk N, Murphy D, Hofman MS, Stricker P. Emmett L, et al. Eur Urol. 2021 Dec;80(6):682-689. doi: 10.1016/j.eururo.2021.08.002. Epub 2021 Aug 28. Eur Urol. 2021. PMID: 34465492 - Multiparametric ultrasound versus multiparametric MRI to diagnose prostate cancer (CADMUS): a prospective, multicentre, paired-cohort, confirmatory study.
Grey ADR, Scott R, Shah B, Acher P, Liyanage S, Pavlou M, Omar R, Chinegwundoh F, Patki P, Shah TT, Hamid S, Ghei M, Gilbert K, Campbell D, Brew-Graves C, Arumainayagam N, Chapman A, McLeavy L, Karatziou A, Alsaadi Z, Collins T, Freeman A, Eldred-Evans D, Bertoncelli-Tanaka M, Tam H, Ramachandran N, Madaan S, Winkler M, Arya M, Emberton M, Ahmed HU. Grey ADR, et al. Lancet Oncol. 2022 Mar;23(3):428-438. doi: 10.1016/S1470-2045(22)00016-X. Lancet Oncol. 2022. PMID: 35240084 Clinical Trial. - Multiparametric MRI in detection and staging of prostate cancer.
Boesen L. Boesen L. Dan Med J. 2017 Feb;64(2):B5327. Dan Med J. 2017. PMID: 28157066 Review. - Should we perform systematic biopsies in case of suspicious MRI for prostate cancer in 2020? A review of literature.
Vesval Q, Fiard G, Villers A, Norris JM, Olivier J. Vesval Q, et al. Prog Urol. 2021 Mar;31(3):147-157. doi: 10.1016/j.purol.2020.09.025. Epub 2020 Nov 12. Prog Urol. 2021. PMID: 33189555 Review.
Cited by
- Added value of shear-wave elastography in the prediction of extracapsular extension and seminal vesicle invasion before radical prostatectomy.
Sun YK, Yu Y, Xu G, Wu J, Liu YY, Wang S, Dong L, Xiang LH, Xu HX. Sun YK, et al. Asian J Androl. 2023 Mar-Apr;25(2):259-264. doi: 10.4103/aja202256. Asian J Androl. 2023. PMID: 36153925 Free PMC article. - Cognitive Targeted Prostate Biopsy Alone for Diagnosing Clinically Significant Prostate Cancer in Selected Biopsy-Naïve Patients: Results from a Retrospective Pilot Study.
Olivetta M, Manfredi C, Spirito L, Quattrone C, Bottone F, Stizzo M, Amicuzi U, Lecce A, Rubinacci A, Romano L, Della Rosa G, Papi S, Tammaro S, Coppola P, Arcaniolo D, Fusco F, De Sio M. Olivetta M, et al. Diagnostics (Basel). 2024 Jul 30;14(15):1643. doi: 10.3390/diagnostics14151643. Diagnostics (Basel). 2024. PMID: 39125520 Free PMC article. - Side-specific, Microultrasound-based Nomogram for the Prediction of Extracapsular Extension in Prostate Cancer.
Pedraza AM, Parekh S, Joshi H, Grauer R, Wagaskar V, Zuluaga L, Gupta R, Barthe F, Nasri J, Pandav K, Patel D, Gorin MA, Menon M, Tewari AK. Pedraza AM, et al. Eur Urol Open Sci. 2022 Dec 28;48:72-81. doi: 10.1016/j.euros.2022.12.005. eCollection 2023 Feb. Eur Urol Open Sci. 2022. PMID: 36743400 Free PMC article. - Efficacy and safety of the new biopsy strategy combining 6-core systematic and 3-core MRI-targeted biopsy in the detection of prostate cancer: Study protocol for a randomized controlled trial.
Zhang C, Tu X, Dai J, Xiong X, Cai D, Yang L, Zhang M, Qiu S, Lin T, Liu Z, Yang L, Wei Q. Zhang C, et al. Front Surg. 2023 Jan 6;9:1058288. doi: 10.3389/fsurg.2022.1058288. eCollection 2022. Front Surg. 2023. PMID: 36684126 Free PMC article. - The role of PSA density in the MRI pathway for prostate cancer diagnostics.
Cash H, Schostak M. Cash H, et al. Prostate Cancer Prostatic Dis. 2023 Sep;26(3):437-438. doi: 10.1038/s41391-022-00579-6. Epub 2022 Jul 26. Prostate Cancer Prostatic Dis. 2023. PMID: 35882951 Free PMC article. No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical